Anti-TDP-43/TARDBP Monoclonal Antibody for WB, IP, IF, IHC, ChIP - Q13148

Core Product Specifications and Parameters

Biological Background: TDP-43 Function and Localization

• TAR DNA-binding protein 43 (TDP-43) is encoded by the TARDBP gene and is also known as ALS10. It belongs to the hnRNP family and contains two RNA recognition motifs (RRMs) and a glycine-rich C-terminal domain.
• Functions as an RNA-binding protein involved in multiple steps of RNA biogenesis and processing (PubMed:23519609). Related references: PMID:23519609
• Preferentially binds GU-repeats via its RRMs, localizing to long introns and 3'UTRs of mRNAs, thereby regulating splicing of many RNAs, including those critical for neuronal survival and neurodegeneration (PubMed:23519609, PubMed:24240615, PubMed:24464995, PubMed:21358640, PubMed:29438978). Related references: PMID:23519609, PMID:24240615, PMID:24464995, PMID:21358640, PMID:29438978
• Plays a role in maintaining mitochondrial homeostasis by processing mitochondrial transcripts (PubMed:28794432) and regulates mRNA stability by recruiting deadenylase to the 3'UTR (PubMed:30520513). Related references: PMID:28794432, PMID:30520513
• In response to oxidative stress, associates with stress granules and stalled ribosomes to promote cell survival (PubMed:19765185, PubMed:23398327). Related references: PMID:19765185, PMID:23398327
• Localizes to the nucleus, cytoplasm, stress granules, and mitochondria. Ubiquitously expressed, with particularly high levels in pancreas, placenta, lung, genital tract, and spleen.
• Undergoes post-translational modifications including phosphorylation, methylation, and ubiquitination, which regulate its function and aggregation propensity. Mutations and mislocalization are linked to amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).

Experimental Guidance and Technical Tips

• The immunogen targets the C-terminal region (aa 300–400) of human TDP-43, which may recognize both full-length and cleaved forms; consider this when interpreting band patterns in Western blot.
• For Western blot, a predominant band near 45 kDa is expected; use appropriate positive controls such as HeLa or brain tissue lysates and validate in your sample system.
• Cross-reactivity with mouse and rat has been documented; confirm performance in your experimental settings, especially for immunohistochemistry where fixation and antigen retrieval may affect staining.
• In immunohistochemistry (IHC), optimize antigen retrieval (e.g., citrate buffer pH 6.0 or EDTA pH 9.0) and detection conditions for each tissue type.
• For immunoprecipitation (IP) and chromatin immunoprecipitation (ChIP), verify antibody suitability for native protein binding; note that TDP-43 is primarily an RNA-binding protein, and DNA interactions may require cross-linking optimization.
• This antibody has been used in ELISA; however, individual assay conditions (e.g., coating buffer, blocking agent) should be optimized to achieve desired sensitivity.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to high-quality IVD raw materials, including this anti-TDP-43 antibody for neurodegenerative disease research. Our comprehensive portfolio features validated antibody pairs, optimized monoclonal and polyclonal antibodies, bulk ancillary reagents, and customized sourcing for rare targets. From concept to clinic, CamelBio supports your assay development with reliable sourcing solutions and technical expertise.